DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), an emerging biopharmaceutical company focused on infectious disease and dermatology, reports it has completed the private sale of an aggregate of $5 million in secured convertible debentures and warrants to three accredited investors. Stifel, Nicolaus & Company, Incorporated served as the lead placement agent.
